Liquid biopsy holds enormous potential in precision oncology—enabling non-invasive, real-time insights into tumor genomics that can guide more accurate treatment decisions. However, its global implementation is still limited by several key challenges.

This webinar will spotlight a strategic collaboration between SOPHiA GENETICS and AstraZeneca, focused on expanding the reach and impact of MSK-ACCESS® powered with SOPHiA DDM™. Through this partnership, technology and clinical expertise are being brought together to create more equitable access to cutting-edge cancer diagnostics around the world.

This session brings together scientific and clinical leaders to discuss their firsthand experiences and the broader implications of such collaborations for cancer care globally.

Why Attend?

While liquid biopsy is often discussed in the context of technical potential, this webinar explores what it takes to turn potential into practice—particularly in settings where access to liquid biopsy is limited.

Learning Objectives

By attending this session, you will:

Understand the technological and analytical foundations of MSK-ACCESS® powered with SOPHiA DDM™, and how it addresses key challenges in liquid biopsy testing such as accuracy, scalability, and reproducibility.

Explore the strategic steps and real-world considerations in building a decentralized global testing network—including how clinical, regulatory, and infrastructural barriers are being addressed collaboratively.

Hear firsthand experience from Synnovis as one of the early adopters of the solution—what implementation looked like, what worked, and how this impacted their clinical research workflows.

As oncology care continues to advance, laboratories are increasingly seeking solutions that offer high-impact, decentralized, and accurate genomic testing. The third session of the Precision Oncology Showcase series introduces a transformative approach to precision oncology, built through collaboration between Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS. 

Join Pierluigi Iapicca, Senior Subject Matter Expert at SOPHiA GENETICS, and Dr. Kojo Elenitoba-Johnson, Chair of the Department of Pathology and Laboratory Medicine at MSK, as they unveil MSK-IMPACT® powered with SOPHiA DDM™, a decentralized comprehensive genomic profiling (CGP) solution that expands access to MSK’s world-class genomic profiling. 

This solution applies the same core technology principles behind MSK-ACCESS® powered with SOPHiA DDM™ to a format compatible with FFPE tissue samples. Using a matched tumor-normal approach, it enhances somatic mutation detection and filters out germline variants, thereby reducing biological false positives. It can also identify clonal hematopoietic variants (CHIP), revealing mutations of true somatic origin. 

MSK-IMPACT® powered with SOPHiA DDM™ offers high concordance with single-site MSK-IMPACT® results across SNVs, indels, TMB, MSI, and copy number alterations, all while leveraging the robust analytics and global scalability of the SOPHiA DDM™ Platform. By combining MSK’s clinical expertise with SOPHiA GENETICS' technological strength, this end-to-end application enables labs to adopt a comprehensive, decentralized CGP model that improves interpretation, enhances accuracy, and expands equitable access to precision oncology. 

Learning Objectives 

• Discover how matched tumor-normal sequencing improves somatic detection and interpretation in decentralized CGP. 
• Learn how MSK-IMPACT® powered with SOPHiA DDM™ delivers high biomarker concordance and enables labs to implement MSK-level CGP. 
• Understand how this platform supports equitable access to precision oncology through a scalable, cloud-based network. 

   

The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.

We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.

Key Discussion Points:

• Decentralizing MSK-ACCESS® – Challenges and solutions for ensuring analytical accuracy, managing site variability, and optimizing workflows.
• Performance & Validation – How the SOPHiA DDM™ Platform maintains high concordance through advanced analytics, noise reduction, and standardized wet-lab processes.
• Real-World Adoption – Leah Thompson, MB (ASCP)CM shares insights on assay verification, workflow efficiency, and the ease of use in routine lab operations.

Learning Objectives

1. Understand the Challenges of Decentralization – Learn about the complexities involved in decentralizing MSK-ACCESS® and how the SOPHiA DDM™ Platform addresses key hurdles such as analytical accuracy, wet-lab standardization, and noise reduction.
2. Evaluate Performance and Real-World Verification – Gain insights into the internal verification study results and real-world data from seven early adopter sites, demonstrating high analytical concordance between the decentralized and single-site versions of MSK-ACCESS®
3. Explore Ease of Adoption and Workflow Efficiency – Understand how MSK-ACCESS® powered with SOPHiA DDM™ offers a streamlined workflow, reliable data quality, and a straightforward implementation process for laboratories.

Explore the Impact on Precision Oncology – Discover how the successful adoption of a decentralized liquid biopsy solution fosters community-driven insights, continuously improving variant calling algorithms and expanding access to high-quality genomic testing.